CONITEC: molecules with a published decision record
142 molecules on this site carry at least one CONITEC decision. Each page compares that decision with every other agency that assessed the same molecule.
| Molecule | Decisions | Agencies | Class |
|---|---|---|---|
| pembrolizumab | 371 | 15 | Antineoplastics |
| nivolumab | 264 | 15 | Antineoplastics |
| adalimumab | 133 | 11 | Immunosuppressants |
| dupilumab | 116 | 15 | Other dermatologicals |
| olaparib | 114 | 15 | Antineoplastics |
| durvalumab | 108 | 15 | Antineoplastics |
| ibrutinib | 108 | 15 | Antineoplastics |
| rituximab | 94 | 9 | Antineoplastics |
| upadacitinib | 93 | 16 | Immunosuppressants |
| ivacaftor | 79 | 12 | Other respiratory |
| secukinumab | 79 | 12 | Immunosuppressants |
| bevacizumab | 77 | 10 | Antineoplastics |
| tocilizumab | 76 | 12 | Immunosuppressants |
| ustekinumab | 71 | 11 | Immunosuppressants |
| infliximab | 69 | 9 | Immunosuppressants |
| lenalidomide | 68 | 13 | Immunosuppressants |
| aflibercept | 67 | 11 | Antineoplastics |
| denosumab | 67 | 11 | Bone diseases |
| etanercept | 67 | 8 | Immunosuppressants |
| blinatumomab | 64 | 14 | Antineoplastics |
| dapagliflozin | 64 | 12 | Diabetes |
| empagliflozin | 64 | 13 | Diabetes |
| everolimus | 61 | 9 | Antineoplastics |
| tofacitinib | 60 | 13 | Immunosuppressants |
| mepolizumab | 59 | 15 | Obstructive airway diseases |
| ipilimumab | 58 | 14 | Antineoplastics |
| trastuzumab | 57 | 9 | Antineoplastics |
| cabozantinib | 56 | 15 | Antineoplastics |
| rivaroxaban | 55 | 11 | Antithrombotics |
| ravulizumab | 54 | 15 | Immunosuppressants |
| semaglutide | 53 | 14 | Diabetes |
| somatropin | 51 | 9 | Pituitary and hypothalamic hormones |
| ruxolitinib | 50 | 12 | Antineoplastics |
| baricitinib | 48 | 14 | Immunosuppressants |
| abemaciclib | 47 | 15 | Antineoplastics |
| vedolizumab | 44 | 12 | Immunosuppressants |
| certolizumab pegol | 43 | 11 | Immunosuppressants |
| golimumab | 43 | 10 | Immunosuppressants |
| omalizumab | 43 | 12 | Obstructive airway diseases |
| ixekizumab | 41 | 11 | Immunosuppressants |
| ranibizumab | 41 | 10 | Ophthalmologicals |
| eculizumab | 39 | 11 | Immunosuppressants |
| evolocumab | 39 | 11 | Lipid modifying agents |
| methotrexate | 38 | 5 | Immunosuppressants |
| alectinib | 37 | 15 | Antineoplastics |
| crizotinib | 35 | 12 | Antineoplastics |
| emicizumab | 35 | 12 | Antihemorrhagics |
| abatacept | 34 | 10 | Immunosuppressants |
| burosumab | 34 | 13 | Bone diseases |
| cetuximab | 34 | 9 | Antineoplastics |
| tacrolimus | 34 | 8 | Immunosuppressants |
| levetiracetam | 33 | 6 | Antiepileptics |
| natalizumab | 33 | 12 | Immunosuppressants |
| pegcetacoplan | 33 | 16 | Ophthalmologicals |
| carfilzomib | 32 | 11 | Antineoplastics |
| pertuzumab | 32 | 13 | Antineoplastics |
| apixaban | 31 | 11 | Antithrombotics |
| benralizumab | 31 | 15 | Obstructive airway diseases |
| bortezomib | 31 | 7 | Antineoplastics |
| canakinumab | 31 | 10 | Immunosuppressants |
| fluticasone | 31 | 8 | Nasal preparations |
| liraglutide | 31 | 9 | Diabetes |
| ramucirumab | 31 | 9 | Antineoplastics |
| fingolimod | 30 | 12 | Immunosuppressants |
| regorafenib | 30 | 12 | Antineoplastics |
| larotrectinib | 29 | 14 | Antineoplastics |
| palbociclib | 29 | 13 | Antineoplastics |
| sofosbuvir | 29 | 11 | Antivirals |
| belimumab | 28 | 12 | Immunosuppressants |
| letermovir | 28 | 14 | Antivirals |
| ocrelizumab | 28 | 12 | Immunosuppressants |
| tafamidis | 28 | 16 | Other nervous system |
| abiraterone | 27 | 10 | Endocrine therapy |
| dasatinib | 27 | 8 | Antineoplastics |
| mesalazine | 27 | 6 | Antidiarrheals / intestinal anti-inflammatories |
| teriparatide | 27 | 8 | Calcium homeostasis |
| brigatinib | 25 | 14 | Antineoplastics |
| cabotegravir | 25 | 10 | Antivirals |
| ivacaftor / lumacaftor | 25 | 11 | Other respiratory |
| raltegravir | 25 | 7 | Antivirals |
| sirolimus | 25 | 8 | Immunosuppressants |
| tramadol | 25 | 4 | Analgesics |
| cinacalcet | 24 | 7 | Calcium homeostasis |
| ciclosporin | 23 | 9 | Ophthalmologicals |
| dabigatran | 23 | 8 | Antithrombotics |
| lanadelumab | 23 | 15 | Other hematological agents |
| rosuvastatin | 23 | 6 | Lipid modifying agents |
| sapropterin | 23 | 11 | Other alimentary tract and metabolism |
| tenofovir | 23 | 4 | Antivirals |
| asciminib | 22 | 15 | Antineoplastics |
| lacosamide | 22 | 7 | Antiepileptics |
| ofatumumab | 22 | 12 | Immunosuppressants |
| risperidone | 22 | 7 | Psycholeptics |
| abrocitinib | 21 | 13 | Other dermatologicals |
| darunavir | 20 | 6 | Antivirals |
| dolutegravir | 20 | 8 | Antivirals |
| glecaprevir / pibrentasvir | 20 | 10 | Antivirals |
| romosozumab | 20 | 13 | Bone diseases |
| ticagrelor | 20 | 9 | Antithrombotics |
| voriconazole | 20 | 7 | Antimycotics |